Find and Pitch Jounalists, Get Your Story Covered

	Profile	Recent Articles on Subject
1	Greg Laub MedPage Today Director of Video at MedPage Today. Screenwriter, previous managing editor. videographyscreenwritingediting	Sequencing in Advanced Urothelial Carcinoma - 17 days ago Adding Tucatinib to T-DM1 Shows PFS Benefit in HER2-Positive Breast Cancer - 11 months ago T-DXd Could Be 'Practice-Changing' in HER2-Expressing Gynecologic Cancers - 12 months ago Ubamatamab Shows Some Activity in Recurrent Ovarian Cancer - 12 months ago Anti-TIGIT Drug Fails to Lift Response Rates in Cervical Cancer Trial - 12 months ago
2	Judy George MedPage Today Medical reporter, writer. Medical reportingartsliterature	Sustained Disease Control in Adolescent Myasthenia Gravis With FcRn Blocker - 30 days ago Nipocalimab Shows Sustained Efficacy in Myasthenia Gravis - about 1 month ago
3	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: Lung cancer drug from iTeos, GSK shows response, boosting TIGIT as a viable target - 2 months ago STAT+: FDA approves innovative T cell immunotherapy for rare soft-tissue cancer - 4 months ago STAT+: Study on Amgen’s ‘bispecific’ immunotherapy could lead to approval in small cell lung cancer - about 1 year ago
4	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	FDA Approves Guselkumab for Treatment of Ulcerative Colitis - 2 months ago FDA Grants Orphan Drug Designation to AISA-021 for Systemic Sclerosis - 2 months ago FDA Accepts NDA and Priority Review Application for Vimseltinib in Tenosynovial Giant Cell Tumors - 3 months ago FDA Approves Amivantamab-Vmjw and Lazertinib for First-Line Treatment of NSCLC - 3 months ago FDA Approves Epcoritamab for Treatment of Relapsed, Refractory Follicular Lymphoma - 5 months ago FDA Approves Idecabtagene Vicleucel for Multiple Myeloma After 2 or More Lines of Therapy - 8 months ago FDA Approves Tocilizumab-aazg as Biosimilar to Actemra for Multiple Indications - 9 months ago FDA Approves 2 Denosumab Biosimilars for All Indications of Reference Products - 9 months ago FDA Approves Rybrevant as First-Line Treatment for NSCLC - 9 months ago FDA Grants Priority Review to Epcoritamab-bysp for Relapsed or Refractory Follicular Lymphoma - 9 months ago FDA Accepts Supplemental New Drug Application for Adagrasib for Colorectal Cancer - 9 months ago FDA Grants Orphan Drug Designation to Tigilanol Tiglate for Soft Tissue Sarcoma - 9 months ago Biosimilar SB8 Is Comparable to Bevacizumab for Non–Small Cell Lung Cancer - 9 months ago Celltrion Seeks Approval From FDA for CT-P47 as Biosimilar of Tocilizumab - 10 months ago Biogen Reprioritizes Alzheimer Disease Franchise, Discontinuing Aducanumab and Advancing Lecanemab - 10 months ago FDA Approves Enfortumab Vedotin, Pembrolizumab for Treatment of Urothelial Cancer - 11 months ago FDA Approves Capivasertib With Fulvestrant for PIK3CA/ALT1/PTEN Alterations Breast Cancer - about 1 year ago Domvanalimab-Containing Regimen Shows Positive Preliminary Data for Upper Gastrointestinal Cancers - about 1 year ago
5	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	STAT+: Can iTeos and GSK solve TIGIT’s troubles? - 2 months ago
6	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC - 2 months ago Targeted First-Line Combo Approved for EGFR-Mutated Lung Cancer - 3 months ago FDA Greenlights First Engineered Cell Therapy for a Solid Tumor - 4 months ago Adding Immunotherapy, Anti-TIGIT in First Line Boosts OS in Esophageal Cancer - 10 months ago Axatilimab Shows Efficacy in Recurrent/Refractory GVHD - 11 months ago Tucatinib Regimen Boosts PFS in Advanced HER2-Positive Breast Cancer - 12 months ago Oncolytic Virus Shows High Response Rates in BCG-Unresponsive Bladder Cancer - 12 months ago Bispecific Antibody Shows Clinical Activity in Recurrent Ovarian Cancer - about 1 year ago Neoadjuvant Cemiplimab Shows Potential as an Option for Cutaneous SCC - about 1 year ago Antibody-Drug Conjugate Improves PFS in Pretreated Breast, Lung Cancers - about 1 year ago
7	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	FDA Grants Breakthrough Therapy Designation to DS-8201a and T-DXd to Treat Metastatic Breast Cancer - 3 months ago Jazz Pharmaceuticals Submits Biologics License Application for Zanidatamab to Treat Biliary Tract Cancer - 8 months ago J&J Submits sBLA To FDA for Guselkumab in Ulcerative Colitis - 8 months ago FDA Approves Pembrolizumab Plus Chemotherapy to Treat Metastatic HER2-Negative Gastric, Gastroesophageal Junction Adenocarcinoma - about 1 year ago
8	Alana Hippensteele, Managing Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	FDA Approves Axatilimab-csfr for cGVHD - 3 months ago FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HER2-Positive Solid Tumors - 8 months ago FDA Approves Tislelizumab-jsgr for Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy - 8 months ago
9	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation	AstraZeneca, Daiichi Sankyo Drug Enhertu Becomes First Tumor-Agnostic ADC Cancer Med - 7 months ago
10	Erin Hunter, Associate Editor Pharmacy Times Actor-writer. Nominated BBC Popcorn. London, United Kingdom actingwritingcomedy	FDA Accepts BLA for Datopotamab Deruxtecan for the Treatment of NSCLC - 9 months ago

Journalists covering sacituzumab govitecan